[D1-A1-01]Welcome Greetings
*Makoto Niwa1, Tomoko Arakawa2(1. The 15th JBF Symposium Executive Committee Chair, Nippon Shinyaku Co., Ltd., 2. The 15th JBF Symposium Executive Committee Vice Chair, Pfizer R&D Japan)
15th JBF Symposium
Feb 5 - Feb 7, 2024MIYAKO MESSE, Kyoto, Japan
You can search for presentations in this event.
Search
15th JBF Symposium
Feb 5 - Feb 7, 2024MIYAKO MESSE, Kyoto, Japan
You can search for presentations in this event.
SearchSearch Results(66)
[D1-A1-02]Opening Remarks for 15th JBF Symposium
*Yoshiro Saito1(1. National Institute of Health Sciences)
[D1-A2-01]About the Checklist for Reliability Standard Studies
*Mutsumi Suzuki1(1. Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association)
[D1-A2-02]Assurance of Study Reliability from the Perspective of Bioanalysis
*Noriyuki Koyama1(1. Japan Bioanalysis Forum, Otsuka Pharmaceutical Co., Ltd.)
[D1-A3-01]Points to Consider Document on Analytical Method Development and Validation of qPCR Methods for Nucleic Acid Biomarkers
*Yoshiro Saito1, Yuchen Sun1(1. National Institute of Health Sciences)
[D1-A3-02]Understanding qPCR Bioanalysis Issues before Validation Planning (DG2017-33) -Update-
*Takeshi Hanada1(1. Daiichi Sankyo Co., Ltd.)
[D1-A3-03]Validation of PCR Assays for Preclinical Studies with Real-World Data
*Haruka Inoue1, Akiko Suzuki1, Yuka Torikai1, Kuniyoshi Abe1, Naoki Kaname1, Chihiro Masuda1, Mirano Yoshikawa1, Yurie Okawa1, Nobuhiro Ijichi1, Yukiko Arimura1, Asako Uchiyama1, Tetsuya Yoshikawa1(1. Shin Nippon Biomedical Laboratories, Ltd. Drug Safety Research Laboratories)
[D1-A3-04]PCR Methods for Bioanalysis in Cell and Gene Therapies
*Mikael Kubista1(1. Czech Academy of Sciences and MultiD Analyses)
[D1-A4-01]Basic Course on the Development of Analytical Methods Using LC/MS/MS
*Takeshi Okuzono1(1. Sekisui Medical Co., Ltd.)
[D1-A4-02]Basic Lecture on Analytical Method Development for ADA in LBA
*Tamiki Mori1(1. Mediford Corporation)
[D2-A1-01]Practical Advice on Immunogenicity Cut-Point Evaluations and Demo of an Excel-based Tool
*Viswanath Devanarayan1(1. Eisai, Inc., and University of Illinois Chicago)
[D2-A1-02]Establishing Appropriate Immunogenicity Assay Cut Points in Oncology Disease Indications
*Michael A Partridge1(1. Regeneron Pharmaceuticals Inc)
[LS2-A-01]Introduction to Analysis Data with 7500 System and Function of SCIEX OS Including Data Integrity.
*Toshifumi Tohda1(1. SCIEX)
[D2-A2-01]Use of Generative AI in Creating Staff Training Materials
*Makoto Niwa1(1. Nippon Shinyaku Co., Ltd.)
[D2-A2-02]The Use of Artificial Intelligence in Medical Publication: an Agency's Perspective
*Mami Hirano1(1. Cactus Life Sciences (part of Cactus Communications))
[D2-A2-03]Providing New-age Behavior Analysis Solutions with Human Sensing Technology and LLM
*Atom Sonoda1(1. Lightblue K.K.)
[D2-A3-01]Ensuring the Integrity of Electronic Data in Non-Clinical studies - A Case Study of Electronic Notebook Data -
*Tadahiro Yoshiyama1(1. Japan Society of Quality Assurance GLP Division / Chugai Pharmaceutical Co., Ltd.)
[D2-A4-01]Toward Implementation of ICH M10 Guideline
*Akiko Ishii-Watabe1, Yoshiro Saito1(1. National Institute of Health Sciences)
[D2-A4-02]One Year into ICH M10: Feedback and Learnings from the Recent EBF Workshop ‘Keeping the Finger on the Pulse’
*Philip Timmerman1(1. European Bioanalysis Forum)
[LS2-B-01]M10 Implementation and Its Impact on Method Validation (LabCorp)
*Luke Bi1(1. Labcorp)
[D2-B2-01]Report of 2022-DG58 " Effective Instruction for the Bioanalyst Career Path"
*Shinsuke Uchihashi1(1. Maruho Co., Ltd.)
[D2-B2-02]Survey Results on the Career of Bioanalysts
*Eiichi Shimada1(1. Japan Bioanalysis Forum, ONO PHARMACEUTICAL CO., LTD.)
[D2-B2-03]Panel Discussion
*Shinsuke Uchihashi1, *Eiichi Shimada2, *Yoshihisa Sano3, *Hideo Matsumoto4(1. Maruho Co., Ltd., 2. ONO PHARMACEUTICAL CO., LTD., 3. Eisai Co., Ltd., 4. JAC Recruitment)
[P2-01]Points to consider for using ADA screening assay signal-to-noise ratio (S/N) as an alternative to titer in immunogenicity assessment (II)
*Kazuko Nishimura1, Hiroko Shibata1, Emu Ikarigawa2, Takuo Suzuki1, Yasuo Suzuki2, Yoshiro Saito3, Akiko Ishii-Watabe1(1. Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 2. Ginza Central Clinic, 3. National Institute of Health Sciences)
[P2-02]Development of a method for acquiring anti-idiotype DNA aptamers against small quantities of antibodies
*Ayana Kuno1, Tiho Hirayama1, Hiriyuki Tasaki1, Aogu Furusho1, Eiji Sugiyama1, Kenichiro Todoroki1(1. Faculty of Pharmac, Univarsal of Shizuoka)
[P2-03]Adsorption measurement of antibody aggregates using Three-dimensional optical wave field microscope
*Satoru NAGATOISHI1, Kensaku SHIMODA2, Kouhei TSUMOTO1, Kazuhiro SUGITA2(1. The University of Tokyo, 2. Otsuka Electronics Co.,Ltd)
[P2-04]Multiplex measurement system for evaluation of CYP induction by Digital PCR
*Yasuhara Hidenori1, Yoko Marutani1, Mayu Igaki1, Shoko Ochiai1, Masahiro Yahata1, Takao Watanabe1, Izuru Miyawaki1(1. Sumitomo Pharma)
[P2-05]Improvements in Bioanalytical Method for Phosphorodiamidate Morphorino Oligonucleotides in Plasma using LC-MS/MS
*Tsubasa Kameyama1, Shunji Imai1, Tetsuhiro Yamada1, Makoto Niwa1, Kazutomi Kusano1(1. Drug Metabolism and Phramcokinetics Research Depertment, Discovery Research Laboratories, NIPPON SHINYAKU CO., LTD.)
[P2-06]Seamless output from analytical method development using LC-MS/MS for cyclic peptides to validation reports using Chromeleon software
*Ryoma Yamamoto1(1. Thermo Fisher Scientific K.K. )
[P2-07]VISUALISATION OF DRUG/METABOLITES AND METABOLISM WITH DESI TQ AND DESI Q-TOF MASS SPECTROMETERS
*Toshiaki Iwata1, Thanai Paxton1, Emmanuelle Claude2, Naysha Munjoma2, Joanne Ballantyne2(1. Nihon Waters K.K., 2. Waters Corporation)
[P2-08]Development of analytical method for structural isomers and enantiomers of aminobutyric acid in biological samples and foods using a highly sensitive chiral resolution labeling reagent L-FDVDA
*Makoto Ozaki1, Motoshi Shimotsuma Shimotsuma1, Takefumi Kuranaga2, Hideaki Kakeya2, Tsunehisa Hirose Hirose1(1. Research and Development Department, Nacalai Tesque, Inc., 2. Department of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University)
[P2-09]Preliminary study for visualization of ketoconazole in skin by MALDI mass spectrometry imaging in the in vitro skin permeability test
*Hiroki Hisasue1, Hiroaki Aikawa1,2, Hideyuki Watanabe3, Mikiko Ootsuka4, Tomoko Koshikawa4, Akihiko Kajiwara4, Kenji Tasaki4, Shin-ichiro Nitta2,5, Norifumi Sakai1, Tomoharu Osada5, Kodo Miura2, Takeshi Kanno3,6, Tsuyoshi Higchi1(1. Safety Assessment Department, Kumamoto Laboratories, Non-clinical Business Segment, Business Management Division, Mediford Corporation, 2. Bioanalytical Department, Clinical Trial Business Segment, Business Management Division, Mediford Corporation, 3. Pathology Department, Kumamoto Laboratories, Non-clinical Business Segment, Business Management Division, Mediford Corporation, 4. Drug Metabolism and Analysis Department, Kashima Laboratories, Non-clinical Business Segment, Business Management Division, Mediford Corporation, 5. Advanced Medical Business Development Department, Corporate Strategy Division, Mediford Corporation, 6. Pathology Department, Kashima Laboratories, Non-clinical Business Segment, Business Management Division, Mediford Corporation)
[P2-10]Optimization of a Method for detecting human Mesenchymal Stem Cells in Mouse Blood and Tissues in non-Clinical study using quantitative PCR
*Yuriko Yatsushiro1, Shoko Kajikawa1, Yuka Ushiku1, Yoshitomo Morozumi1, Hiroyuki Komatsu1, Akihiro Kanno1(1. CMIC Pharma Science Co.,Ltd.)
[P2-11]Study of the Development of an LC-TOF/MS Method for Cyclic Peptides in Biological Samples
*Kayo Iwasaki1, Suguru Fukuda1, Mitsuhiko Kawabata1, Katsunori Ieki1(1. Shin Nippon Biomedical Laboratories, Ltd.)
[P2-12]Optimization of bioanalysis methods for nucleic acid drugs
*Takuma Shigeyama1, Kazuyuki Murata1, Risa Hamada1, Takeru Yamaguchi1(1. Sumika Chemical Analysis Service, Ltd.)
[DGP2-01]DG2023-60: Lifecycle Management of Anti-Drug Anitibody Assays
*Tsunenori Nakazawa1, Yukihiro Otsuka2, Tomoko Kojima3, Sae Niimura4, Suguru Hanari5, Kosuke Fukuda6, Motohiko Morihara7, Yukako Taniguchi4(1. Daiichi Sankyo Co., Ltd., 2. Sekisui Medical Co., Ltd., 3. Sunplanet Co., Ltd., 4. Shin Nippon Biomedical Laboratories, Ltd., 5. CMIC, Inc., 6. Sumitomo Pharma Co., Ltd., 7. Ono Pharmaceutical Co., Ltd.)
[DGP2-02]DG2023-62: Recommendations for Achieving Digital Transformation in the Field of Bioanalysis
Tsuyoshi Kawahara1, Ayaka Kondo2, Naoko Nakai3, *Hisao Nagaya4(1. SEKISUI MEDICAL CO., LTD., 2. SHIONOGI & CO., LTD., 3. DAIICHI SANKYO COMPANY, LIMITED, 4. Synplogen Co., Ltd.)
[DGP2-03]DG2023-64: The Proposal of a Roadmap to Provide the Opportunity to Step up from a Beginner to a Full-fledged LC-MS/MS Analyst
*Hironosuke Kurisu1, Yusuke Akagi2, Shinsuke Asano3, Toshimasa Ito4, Yuko Ueda5, Yo Ehara6, Yukihiro Matsuda7, Ryotaro Yagi8, Ryo Yamato9, Yuki Yoshimura5(1. Pfizer R&D Japan G.K., 2. JAPAN TOBACCO INC., 3. CMIC Pharma Science Co., 4. Sumitomo Pharma Co., 5. Sumika Chemical Analysis Service, Ltd., 6. Kawasaki City Institute for Public Health., 7. EA Pharma Co., Ltd., 8. Toray Industries, Inc., 9. Mediford Corporation.)
[LS2-C-01]Glycoanalysis of Biopharmaceuticals (Otsuka Phamaceuticals)
*Izumi Sakamoto1(1. GlyTech, Inc.)
[LS2-D-01]A Complete Solution for Accelerating Oligonucleotide Analysis
～From Preprocessing to Detection～ (Waters)
*Hiroko Iwasaki1(1. Nihon Waters K.K.)
[D3-A1-01]Feedback from the JBF Workshop for ICH-M10 Guideline in 2023
*Yuki Takamatsu1(1. Japan Bioanalysis Forum, Takeda Pharmaceutical Co., Ltd.)
[D3-A1-02]Experiences and Lessons Learned from the AAPS Bioanalytical Community One Year after the Implementation of ICH-M10
*Faye Vazvaei1(1. MSD)
[LS3-A-01]Watson LIMS for Bioanalysis Workflow and Recent DI Trends and Implementation Examples (Thermo)
*Takayuki Matsunuma1(1. Thermo Fisher Scientific K.K.)
[D3-A2-01]Research in Development and Standardization of LC-MS/MS Based Peptide Bioanalysis
*Kosuke Saito1(1. National Institute of Health Sciences)
[D3-A2-02]Introduction of Analytical Tips and Examples of Analysis When Quantitatively Measuring Peptides Using LC/MS
*Chie Inagaki1(1. SCIEX)
[D3-A2-03]Various Approaches to Some Challenges in Peptides Bioanalysis
*Ryoma Yamamoto1(1. Thermo Fisher Scientific K.K.)
[D3-A2-04]Basics of LC/MS and Tips in Peptide Analysis
*Junna Nakazono1(1. Shimadzu Corporation)
[LS3-B-01]Precautions and Know-how in Using Ultrapure Water for LCMS (ELGA)
*Yoshifumi Kuroki1(1. ELGA LabWater)
[P3-01]デジタルPCR及び定量PCRによる生体試料中のアデノ随伴ウイルスベクター定量法の構築
*Yoichi Tanaka1, Sayaka Hamano1, Ryosuke Ide2, Kyoko Watanabe3, Kosuke Shimada4, Makiko Motoi5, Takanori Mori6, Kazuhiro Tsukamoto7, Toshihiko Ueda8, Ruri Hanajiri1, Yoshiro Saito1(1. National Institute of Health Sciences, 2. Mitsubishi Tanabe Pharma Corporation, 3. Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., 4. Thermo Fisher Scientific Life Technologies Japan Ltd., 5. Global Drug Metabolism and Pharmacokinetics, Eisai Co., Ltd., 6. Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd., 7. Bioanalysis Research Department, CMIC Pharma Science Co.,Ltd., 8. Mediford Corporation)
[P3-02]Improvement of the enzyme-linked aptamer assay for bioanalysis of therapeutic monoclonal antibodies
*Chiho Hirayama1, Ayana Kuno1, Hiroyuki Tasaki2, Nao Kobayashi2, Aogu Furusyo1, Eiji Sugiyama1, Kenichiro Todoroki1(1. School of Pharmaceutical Science, University of Shizuoka, 2. Graduate School of Integrated Pharmaceutical and Nutritional Science, University of shizuoka)
66 results ( 1 - 50 )
- 1